Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516250-22-00

Acronym

CMG012022

Enrollment

Registered

2024-09-20

Start date

2023-04-17

Completion date

Unknown

Last updated

2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and who have documented disease progression during, or after, their most recent therapy., The study will enroll adult participants with RRMM who have been previously treated with at least 1 prior line of therapy

Brief summary

1. ORR, defined as the percentage of participants with a Partial Response (PR) or better (i.e., PR, Very Good Partial Response (VGPR), Complete Response (CR)) 2. Incidence rate of Grade ≥3 ocular adverse events according to the keratopathy visual acuity (KVA) scale

Interventions

DRUGBORTEZOMIB

DRUGDEXAMETHASONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. ORR, defined as the percentage of participants with a Partial Response (PR) or better (i.e., PR, Very Good Partial Response (VGPR), Complete Response (CR)) 2. Incidence rate of Grade ≥3 ocular adverse events according to the keratopathy visual acuity (KVA) scale	—

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026